Literature DB >> 25457967

Scientific innovation's two Valleys of Death: how blood and tissue banks can help to bridge the gap.

Sean D A Thompson.   

Abstract

Most biomedical basic research in the United States takes place at universities and research institutes and is funded by federal grants. Basic research is awarded billions of federal dollars every year, enabling new discoveries and greater understanding of the fundamental science that makes new innovations and therapies possible. However, when basic research yields an invention of practical use and the research evolves from basic to applied, the playing field changes. Pre-technology licensing federal dollars all but disappear, and innovations rely predominantly on private funding to support the full path from bench to bedside. It is along this path that the scientific advance faces two Valleys of Death. These sometimes insurmountable development stages are the product of the innovation's inherent financial, business and investment risks. Well-planned and executed in vivo studies using quality biological materials demonstrating proof-of-concept is often the key to bridging these gaps, and blood and tissue banks offer unique services and resources to enable this process.

Mesh:

Year:  2014        PMID: 25457967      PMCID: PMC4236033          DOI: 10.1089/scd.2014.0379

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  2 in total

1.  Translational research: crossing the valley of death.

Authors:  Declan Butler
Journal:  Nature       Date:  2008-06-12       Impact factor: 49.962

Review 2.  The basics of preclinical drug development for neurodegenerative disease indications.

Authors:  Karen L Steinmetz; Edward G Spack
Journal:  BMC Neurol       Date:  2009-06-12       Impact factor: 2.474

  2 in total
  2 in total

Review 1.  Hurdles to clinical translation of human induced pluripotent stem cells.

Authors:  Evgenios Neofytou; Connor Galen O'Brien; Larry A Couture; Joseph C Wu
Journal:  J Clin Invest       Date:  2015-07-01       Impact factor: 14.808

Review 2.  Induced Pluripotent Stem Cell-Derived Corneal Cells: Current Status and Application.

Authors:  Nasif Mahmood; Taylor Cook Suh; Kiran M Ali; Eelya Sefat; Ummay Mowshome Jahan; Yihan Huang; Brian C Gilger; Jessica M Gluck
Journal:  Stem Cell Rev Rep       Date:  2022-08-01       Impact factor: 6.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.